Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rafael Holdings, Inc.

NYSE: RFL · Life Sciences · 4 alerts · CIK 1713863

Share price
$0.9701Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rafael Holdings, Inc. filings on SEC EDGAR ↗

4:32 PM ET 8-K
Investor Presentation

Rafael Holdings Investor Presentation

Rafael Holdings filed a formal investor presentation deck (Exhibit 99.1) following its October 2026 NDA submission for remibetadex. The presentation highlights topline Phase 3 data in Niemann-Pick Disease Type C (NPC), including a prespecified analysis showing a 71% relative slowing of disease progression in a specific patient subgroup.

11:36 AM ET 10-K
Financial Results

Rafael Holdings FY 2026 Results: Net Loss of $29.6M, Loss Narrows

Rafael Holdings, Inc. faces substantial doubt regarding its ability to continue as a going concern, holding $22.1 million in cash as of July 31, 2026. The company recently submitted an NDA for Trappsol® Cyclo™ following a Phase 3 trial that failed its primary endpoint in the overall population but showed statistical significance in a prespecified subgroup.

Key figure
Net loss $29.6M
8:16 AM ET 8-K
Financial Results

Rafael Holdings Financial Results

Rafael Holdings reported its fourth quarter and full fiscal year 2026 results, highlighted by a net loss of $29.6 million for the year. The company also announced that its subsidiary, Cyclo Therapeutics, submitted a New Drug Application to the FDA for remibetadex to treat Niemann-Pick Disease Type C.

Term
FY2026
7:24 AM ET 8-K
Clinical Trial Data

Rafael Holdings Clinical Trial Data

Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in 94 patients with Niemann-Pick Disease Type C. While the study did not achieve statistical significance on the primary endpoint in the overall population, a prespecified analysis of patients on background therapy (83% of the study) showed a statistically significant slowing of disease progression. The company remains on track to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2026.

Counterparty
Cyclo Therapeutics, LLC
Term
96 weeks
Earnings call
Sep 30, 2026, 8:30 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.